Efficacy and safety analysis of radium-223 in patients with prostate cancer castration-resistant and bone metastasis

Objectives Radium-223 is a radiopharmaceutical with alpha waves emission. Recently, clinical discussion focus on using the combination of Radium-223 with abiraterone or enzalutamide, or previous chemotherapy. We aimed to evaluate the efficacy and safety of radium-223 in patients with prostate cancer...

Full description

Autores:

Alfonso Quiñones, PA
Carrasquilla-Sotomayor, M
Alvis-Zakzuk, NJ
Romero Prada, ME
Alvis-Guzmán, N
Huerfano, LM

Tipo de recurso:

Article of journal

Fecha de publicación:

2018

Institución:

Corporación Universidad de la Costa

Repositorio:

REDICUC - Repositorio CUC

Idioma:

eng

OAI Identifier:

oai:repositorio.cuc.edu.co:11323/4715

Acceso en línea:

https://hdl.handle.net/11323/4715
https://repositorio.cuc.edu.co/

Palabra clave:

Radium-223
Radiofármaco con emisión de ondas alfa
Abiraterona o enzalutamida
Radio-223
Radiopharmaceutical with alpha wave emission
Abiraterone or enzalutamide

Rights

openAccess

License

Attribution-NonCommercial-ShareAlike 4.0 International